Compare · MRK vs YARW
MRK vs YARW
Side-by-side comparison of Merck & Company Inc. (MRK) and Yarrow Bioscience Inc. (YARW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and YARW operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $364.26B, about 2171.4x YARW ($167.8M).
- Over the past year, MRK is up 59.2% and YARW is down 6.2% - MRK leads by 65.4 points.
- MRK has been more active in the news (18 items in the past 4 weeks vs 11 for YARW).
- MRK has more recent analyst coverage (25 ratings vs 2 for YARW).
- Company
- Merck & Company Inc.
- Yarrow Bioscience Inc.
- Price
- -
- -
- Market cap
- $364.26B
- $167.8M
- 1M return
- +1.70%
- -5.53%
- 1Y return
- +59.16%
- -6.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 18
- 11
- Recent ratings
- 25
- 2
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Yarrow Bioscience Inc.
Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, a potential first-in-class anti-thyroid stimulating hormone receptor monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease and thyroid eye disease.
Latest MRK
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
- FDA Approval for WELIREG issued to MERCK SHARP DOHME
- SEC Form 10-Q filed by Merck & Company Inc.
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- SEC Form 4 filed by Director Diaz Paul J
- New insider Diaz Paul J claimed ownership of 296 shares (SEC Form 3)
- Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Latest YARW
- SEC Form SCHEDULE 13G filed by Yarrow Bioscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Yarrow Bioscience Inc.
- Jefferies initiated coverage on Yarrow Bioscience with a new price target
- SEC Form S-8 filed by Yarrow Bioscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Yarrow Bioscience Inc.
- SEC Form SCHEDULE 13G filed by Yarrow Bioscience Inc.
- SEC Form 10-Q filed by Yarrow Bioscience Inc.
- Yarrow Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update
- Guggenheim initiated coverage on Yarrow Bioscience with a new price target